

## MINUTES

**Wednesday 14 December 2022  
2:00pm – 3:00pm (AEDT)**

Attendees: Marissa Ryan (co-chair), Geeta Sandhu (co-chair), Kimberley-Ann Kerr (committee member, minutes), Courtney Oar (committee member), Chi Hao La (committee member), Sonia Cuan (committee member), Kate Wright (committee member), Jim Siderov, Bharti Tailor, Sohena R, Sarah Heward, Helen Gougougiannis, Neil Lam (committee member – from 3pm)

AGENDA ITEM		RESPONSIBLE OFFICER
1. Welcome to Country		MR/GS
2. Apologies/Conflicts of Interest	Apologies: <ul style="list-style-type: none"> <li>• Sam Nakagawa</li> <li>• Marliese Alexander (committee member)</li> <li>• Dan McKavanagh</li> </ul> No conflicts of interest declared	MR/GS
3. Previous Minutes		MR/GS
4. Chair's report	Input into responses for: <ul style="list-style-type: none"> <li>- National Medicines Policy</li> <li>- Integrated oncology white paper</li> <li>- Efficient Funding of Chemotherapy</li> </ul> Input into Marrayalyan Attended MOGA round table New collaborations with global oncology Moving forward in 2023: <ul style="list-style-type: none"> <li>- Research fellowships led by Marliese Alexander</li> <li>- Collaborate with BOPA and CAPHO for educational webinars</li> </ul>	MR/GS
5. Verbal updates on CPG courses	Foundation course: <ul style="list-style-type: none"> <li>- 18-19 June in Sydney</li> <li>- Approx 100 delegates</li> <li>- 90% rated course topics as excellent or very good and</li> </ul>	CO/KK

	<p>would recommend course to colleagues</p> <ul style="list-style-type: none"> <li>- Feedback is shaping format for future courses with more interactivity</li> <li>- 2023 course on 24-25 June in Sydney</li> </ul> <p>Advanced course:</p> <ul style="list-style-type: none"> <li>- 3-4 September in Melbourne</li> <li>- Approx. 100 delegates</li> <li>- All states (except NT) and NZ represented</li> <li>- 97% rated it as good or excellent</li> <li>- Clinical updates and workshops</li> </ul> <p>Pre-ASM workshop</p> <ul style="list-style-type: none"> <li>- 29 November</li> <li>- Complimentary topics to ASM with afternoon clinical development workshop sponsored by eviQ</li> <li>- Strong positive feedback</li> </ul> <p>Sarah Heward from WA advocated for hybrid in person/virtual workshops. This will be taken on board</p> <p>Many delegates not COSA/CPG members – CO asked attendees to encourage colleagues to join COSA CPG</p> <p>Bharti Tailor asked if there are opportunities for non-exec members to participate in teaching/organisational component of workshops. MR asked members to express their interest to the exec so this could be taken into consideration</p>	
<p><b>6. COSA ASM 2023 Update</b></p>	<p>Chi Hao La and Marliese Alexander representing CPG on program committee</p> <p>To be held in Melbourne</p> <p>Primary theme breast cancer; secondary theme gynaecological cancer</p> <p>50<sup>th</sup> anniversary of ASM in 2023</p> <p>Medicines matter session to be held again</p> <p>CPG nominated international speaker Faye Coe from The Christie in the UK (not yet accepted)</p>	<p>CHL/MA</p>
<p><b>7. Future activities</b></p>	<ul style="list-style-type: none"> <li>- Advanced course to become advanced program with a workshop and webinars</li> <li>- Build bigger partnerships with other special interest groups</li> </ul>	<p>MR/GS</p>

UNOFFICIAL

	<ul style="list-style-type: none"> <li>- Continue BOPA collaboration. Had a BOPA member attend the COSA ASM. 2 tickets will be available to COSA members for BOPA symposium next year</li> <li>- Marliese writing a program for research fellowship. Members to advise if they are interested</li> <li>- Safe prescribing, dispensing and administration guidelines will be updated in the future. No set dates yet – membership to be advised</li> <li>- COSA website revamped</li> </ul>	
<p><b>8. CPG Executive Committee and Membership update</b></p>	<p>Zainab Reslan on maternity leave. Neil Lam has stepped onto committee All other executive committee members will be continuing next year</p>	<p>MR/GS</p>
<p><b>9. Other Business</b></p>	<p>Update for safe handling of monoclonal antibodies produced by MR, NL, KW and JS. In process of review by journal. Unable to be circulated as they are in the process of publication.</p> <p>Australian cancer plan consultation period still open</p> <p>JS queried why AGM was not held during ASM. All group AGMs now held separately from the ASM to allow more members to attend. The TOR states Groups must hold an annual general meeting, preferably at the COSA Annual Scientific Meeting therefore it doesn't have to be at the ASM nor face-to-face</p>	<p>MR/GS</p>
<p><b>10. Next Meeting (TBC)</b></p>	<p>TBC</p>	